PropThink: Evidence Suggests Likely Approval of Cabozantinib for Metastatic Medullary Thyroid Cancer

[ACN Newswire] – By David Sobek Exelixis (NASDAQ:EXEL) has a Prescription Drug User Fee Act (PDUFA) action date on November 29 th , 2012 for cabozantinib as a treatment for patients with progressive, unresectable, locally … more

View todays social media effects on EXEL

View the latest stocks trending across Twitter. Click to view dashboard